Galapagos Knocked By Knee Osteoarthritis Fail
Servier-Partnered Drug Shows No Activity in Phase II
Executive Summary
Still reeling from the FDA rejection of its JAK inhibitor filgotinib for rheumatoid arthritis, the Belgium-headquartered biotech's ADAMTS-5 inhibitor developed with France's Servier is sunk after failing to significantly reduce cartilage loss compared with placebo in an OA trial.
You may also be interested in...
Galapagos Keeps Analysts Guessing About Future Plans
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.
Pharma R&D Legend Stoffels To Take Helm At Galapagos
The troubled Belgian biotech has pulled off a major coup in hiring Paul Stoffels, the architect of J&J's R&D successes over the last decade, as its new CEO.
J.P. Morgan Day 4: Preparing For The Year Ahead
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Updates from Galapagos, Ipsen, LG Chem, Hanmi and Fosun; experts discuss deal and financial outlook at Biotech Showcase, plus the impact of RMAT and the changing landscape for rare diseases.